Palatin Technologies (PTN) Expected to Announce Earnings on Tuesday

Palatin Technologies (NYSEAMERICAN:PTN) is expected to issue its Q3 2026 results before the market opens on Tuesday, May 19th. Analysts expect the company to announce earnings of ($1.2433) per share and revenue of $1.2830 million for the quarter. Parties may review the information on the company’s upcoming Q3 2026 earning report for the latest details on the call scheduled for Wednesday, May 20, 2026 at 11:00 AM ET.

Palatin Technologies Stock Down 2.4%

Palatin Technologies stock opened at $19.00 on Tuesday. Palatin Technologies has a 1-year low of $4.25 and a 1-year high of $31.00. The business’s 50-day moving average price is $20.60.

Institutional Investors Weigh In On Palatin Technologies

A number of large investors have recently made changes to their positions in the business. Geode Capital Management LLC purchased a new position in shares of Palatin Technologies during the fourth quarter valued at approximately $272,000. Jane Street Group LLC bought a new position in Palatin Technologies in the 4th quarter worth $166,000. Bleichroeder LP bought a new position in Palatin Technologies in the 4th quarter worth $120,000. RA Capital Management L.P. purchased a new stake in shares of Palatin Technologies in the 4th quarter worth about $1,077,000. Finally, Logos Global Management LP bought a new stake in shares of Palatin Technologies during the 4th quarter valued at about $2,153,000. 11.50% of the stock is currently owned by institutional investors.

Palatin Technologies Company Profile

Palatin Technologies, Inc (NYSE American: PTN) is a clinical-stage biopharmaceutical company focused on the development of receptor-targeted peptide therapeutics. The company concentrates on designing and advancing peptide- and small-molecule programs that selectively target specific receptor systems with the goal of treating endocrine, inflammatory and cardiovascular-related disorders. Palatin’s approach emphasizes receptor specificity to improve therapeutic profiles and reduce off-target effects commonly seen with less selective agents.

Palatin’s activities center on preclinical and clinical development, regulatory interaction and the pursuit of strategic partnerships or licensing arrangements to support late-stage development and commercialization.